Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
Copper metabolism MURR1 domain 1 (COMMD1) protein is a multifunctional protein, and its expression has been correlated with patients' survival in different types of cancer. In vitro studies revealed that COMMD1 plays a role in sensitizing cancer cell lines to cisplatin, however, the mechanism a...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5082896?pdf=render |
id |
doaj-34a04406c6ee4dfaadf1962699b0b1fe |
---|---|
record_format |
Article |
spelling |
doaj-34a04406c6ee4dfaadf1962699b0b1fe2020-11-25T00:08:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011110e016538510.1371/journal.pone.0165385Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.Alina FedoseienkoHylke W WieringaG Bea A WismanEvelien DuikerAnna K L ReynersMarten H HofkerAte G J van der ZeeBart van de SluisMarcel A T M van VugtCopper metabolism MURR1 domain 1 (COMMD1) protein is a multifunctional protein, and its expression has been correlated with patients' survival in different types of cancer. In vitro studies revealed that COMMD1 plays a role in sensitizing cancer cell lines to cisplatin, however, the mechanism and its role in platinum sensitivity in cancer has yet to be established. We evaluated the role of COMMD1 in cisplatin sensitivity in A2780 ovarian cancer cells and the relation between COMMD1 expression and response to platinum-based therapy in advanced stage high-grade serous ovarian cancer (HGSOC) patients. We found that elevation of nuclear COMMD1 expression sensitized A2780 ovarian cancer cells to cisplatin-mediated cytotoxicity. This was accompanied by a more effective G2/M checkpoint, and decreased protein expression of the DNA repair gene BRCA1, and the apoptosis inhibitor BCL2. Furthermore, COMMD1 expression was immunohistochemically analyzed in two tissue micro-arrays (TMAs), representing a historical cohort and a randomized clinical trial-based cohort of advanced stage HGSOC tumor specimens. Expression of COMMD1 was observed in all ovarian cancer samples, however, specifically nuclear expression of COMMD1 was only observed in a subset of ovarian cancers. In our historical cohort, nuclear COMMD1 expression was associated with an improved response to chemotherapy (OR = 0.167; P = 0.038), although this association could not be confirmed in the second cohort, likely due to sample size. Taken together, these results suggest that nuclear expression of COMMD1 sensitize ovarian cancer to cisplatin, possibly by modulating the G2/M checkpoint and through controlling expression of genes involved in DNA repair and apoptosis.http://europepmc.org/articles/PMC5082896?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alina Fedoseienko Hylke W Wieringa G Bea A Wisman Evelien Duiker Anna K L Reyners Marten H Hofker Ate G J van der Zee Bart van de Sluis Marcel A T M van Vugt |
spellingShingle |
Alina Fedoseienko Hylke W Wieringa G Bea A Wisman Evelien Duiker Anna K L Reyners Marten H Hofker Ate G J van der Zee Bart van de Sluis Marcel A T M van Vugt Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS ONE |
author_facet |
Alina Fedoseienko Hylke W Wieringa G Bea A Wisman Evelien Duiker Anna K L Reyners Marten H Hofker Ate G J van der Zee Bart van de Sluis Marcel A T M van Vugt |
author_sort |
Alina Fedoseienko |
title |
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. |
title_short |
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. |
title_full |
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. |
title_fullStr |
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. |
title_full_unstemmed |
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. |
title_sort |
nuclear commd1 is associated with cisplatin sensitivity in ovarian cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Copper metabolism MURR1 domain 1 (COMMD1) protein is a multifunctional protein, and its expression has been correlated with patients' survival in different types of cancer. In vitro studies revealed that COMMD1 plays a role in sensitizing cancer cell lines to cisplatin, however, the mechanism and its role in platinum sensitivity in cancer has yet to be established. We evaluated the role of COMMD1 in cisplatin sensitivity in A2780 ovarian cancer cells and the relation between COMMD1 expression and response to platinum-based therapy in advanced stage high-grade serous ovarian cancer (HGSOC) patients. We found that elevation of nuclear COMMD1 expression sensitized A2780 ovarian cancer cells to cisplatin-mediated cytotoxicity. This was accompanied by a more effective G2/M checkpoint, and decreased protein expression of the DNA repair gene BRCA1, and the apoptosis inhibitor BCL2. Furthermore, COMMD1 expression was immunohistochemically analyzed in two tissue micro-arrays (TMAs), representing a historical cohort and a randomized clinical trial-based cohort of advanced stage HGSOC tumor specimens. Expression of COMMD1 was observed in all ovarian cancer samples, however, specifically nuclear expression of COMMD1 was only observed in a subset of ovarian cancers. In our historical cohort, nuclear COMMD1 expression was associated with an improved response to chemotherapy (OR = 0.167; P = 0.038), although this association could not be confirmed in the second cohort, likely due to sample size. Taken together, these results suggest that nuclear expression of COMMD1 sensitize ovarian cancer to cisplatin, possibly by modulating the G2/M checkpoint and through controlling expression of genes involved in DNA repair and apoptosis. |
url |
http://europepmc.org/articles/PMC5082896?pdf=render |
work_keys_str_mv |
AT alinafedoseienko nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT hylkewwieringa nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT gbeaawisman nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT evelienduiker nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT annaklreyners nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT martenhhofker nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT ategjvanderzee nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT bartvandesluis nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer AT marcelatmvanvugt nuclearcommd1isassociatedwithcisplatinsensitivityinovariancancer |
_version_ |
1725415568501112832 |